Insider Transactions in Q1 2022 at Syndax Pharmaceuticals Inc (SNDX)
Insider Transaction List (Q1 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 02
2022
|
Martin H. Huber Jr. |
BUY
Grant, award, or other acquisition
|
Direct |
16,000
+50.0%
|
-
|
|
Feb 02
2022
|
William Meury |
BUY
Grant, award, or other acquisition
|
Direct |
16,000
+33.33%
|
-
|
|
Feb 02
2022
|
Jennifer Jarrett |
BUY
Grant, award, or other acquisition
|
Direct |
16,000
+33.33%
|
-
|
|
Feb 02
2022
|
Fabrice Egros |
BUY
Grant, award, or other acquisition
|
Direct |
16,000
+33.33%
|
-
|
|
Feb 02
2022
|
Pierre Legault |
BUY
Grant, award, or other acquisition
|
Direct |
16,000
+33.33%
|
-
|
|
Feb 02
2022
|
Keith Katkin |
BUY
Grant, award, or other acquisition
|
Direct |
16,000
+33.33%
|
-
|
|
Feb 02
2022
|
Dennis Podlesak |
BUY
Grant, award, or other acquisition
|
Direct |
32,000
+29.69%
|
-
|
|
Feb 01
2022
|
Alexander Nolte Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
968
-100.0%
|
$15,488
$16.65 P/Share
|
|
Feb 01
2022
|
Peter Ordentlich Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,412
-100.0%
|
$22,592
$16.65 P/Share
|
|
Jan 31
2022
|
Michael L. Meyers SVP, Chief Medical Officer |
BUY
Other acquisition or disposition
|
Direct |
1,714
+6.86%
|
$20,568
$12.39 P/Share
|
|
Jan 31
2022
|
Alexander Nolte Chief Accounting Officer |
BUY
Other acquisition or disposition
|
Direct |
968
+50.0%
|
$11,616
$12.39 P/Share
|
|
Jan 31
2022
|
Peter Ordentlich Chief Scientific Officer |
BUY
Other acquisition or disposition
|
Direct |
1,412
+50.0%
|
$16,944
$12.39 P/Share
|